Tx for AML With Biomarkers
Selecting Therapy for AML With Predictive Biomarkers or Actionable Alterations
Eytan M. Stein
Eytan M. Stein, MD

Pretest

Progress
1 2
Course Completed
Please answer the questions below.
1.
Which of the following statements are true regarding Enteral to IV Mix ups:
2.
When considering the hierarchy of prevention strategies:
3.
Why are ENFit connectors needed?
4.
What is the approximate adoption rate of ENFit connectors in North America?
5.
When using an ENFit syringe, what is the risk of not removing medication in the dead space prior to administration?